BMS sales rep joins fight for overtime pay

For those of you tracking the sales-rep overtime fight, here's another lawsuit to add to the list. A former rep for Bristol-Myers Squibb has sued the company for back pay, and he's seeking class-action status for the suit. The suit claims that Jeffrey Bethune, who left the company in 2008, is entitled to OT because he--and his fellow reps--was not exempt from overtime rules under the Fair Labor Standards Act.

According to Bethune's attorney, Charles Joseph of Joseph, Herzfeld Hester & Kirschenbaum, the Department of Labor is on the reps' side; he cites the feds' friend of the court briefs supporting reps' OT claims. In a statement about the case, Joseph also mentions decisions from the Second Circuit appeals court, which ruled in favor of overtime pay for Novartis reps and, in a separate case, for Schering-Plough salespeople.

What Joseph doesn't mention is that other courts have ruled against overtime pay for reps--including another appeals court. In two separate cases, the Third Circuit determined that Johnson & Johnson and AstraZeneca reps should be salaried employees ineligible for overtime. And as Pharmalot notes, one federal district judge sided with Alpharma--now a King Pharmaceuticals unit, and soon to be part of Pfizer--in an overtime case.

- read the release from Joseph, Herzfeld
- get the Pharmalot coverage

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.